Thanks to increasing environmental awareness among people worldwide, there's a growing commitment to sustainable practices across industries. The healthcare
sector, including pharmacies, is no exception.
Recognising the fact that 'climate crisis is a health crisis', 124 countries signed a new Declaration on Climate and Health at the first-ever Health Day at the
United Nations climate change conference, COP28 Dubai, which was held on 3 December 2023.
The declaration acknowledged the need to prepare healthcare systems to cope with climate change and accelerate actions to protect communities.
Welcoming the declaration, Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO) emphasized the need to build "climate-resilient and
low-carbon" health systems to protect the health of both the planet and people.
Pharmacies play a crucial role in providing essential medications and healthcare services to the community, but their operations can have environmental implications.
Global consumer healthcare company Haleon has launched a new centre of excellence for a global leader in consumer health which will bring together world leading
academics in human behaviour and frontline healthcare professionals including community pharmacists.
Unveiled at the International Pharmaceutical Federation (FIP) Congress in 'sunny' Seville, Spain on September 20, the Centre will operate as a community of healthcare
professionals and specialists in behavioural science, health psychology and the social sciences to solve some of the most pressing everyday health challenges.
Named the Centre for Human Sciences (CHS) the initiative will be the first major programme for healthcare professionals since the Haleon's launch on July 18 as an
independent, global leader in consumer health.
The Centre's mission is to support practising health professionals - pharmacists, pharmacy assistants and dental professionals - in serving their patients and
communities. Combining science with deep human understanding, CHS will bring expertise in physiology together with human sciences to deliver real world-solutions
and tangible interventions, resulting in measurable improvements in health outcomes through sustained behavioural change.
The Centre is facilitated by Robert Horne, professor of Behavioural Medicine at UCL School of Pharmacy, who started his career as a practising pharmacist but later
chose to become a behavioural scientist when he saw an opportunity to address issues around psycho-social factors that acted as a hindrance in pharmacy practice.
Speaking to me in an exclusive three-way conversation alongside Tess Player, the global head of healthcare professional & health influencer marketing at Haleon, on
the sidelines of the FIP Congress 2022, Prof Horne expanded on what the Centre was all about and how it would work.
"We've got some good ideas, but it's not a pre-filled prescription that we're going to deliver at scale from the start. What Haleon is t
The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation.
Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new
prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and
help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships.
Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium
(IRDiRC) Task Force on Drug Repurposing Guidebook.
Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma
industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.
The Royal Pharmaceutical Society and Scottish Academy of Medical Royal Colleges co-hosted the NHS Education for Scotland annual virtual conference to discuss
the environmental impact of prescribing.
One of the conclusions drawn from the conference on Thursday (April 28) stressed on environmentally sustainable prescribing should be embedded in undergraduate
and postgraduate health care education.
Delegates at the session said they or their teams needed more education. They also needed more information and resources when prescribing to be able to consider
environmental issues.
Sharon Pfleger, Consultant in Pharmaceutical Public Health at NHS Highland, told the session: "There's a lot of work to be done to reduce carbon emissions. The
NHS has identified the use of metered-dose inhalers as its second biggest cause of carbon emissions as the propellant gases have significant global warming potential.
The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair.
DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly.
With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca.
She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services.
In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to
prepare for the proposed spin out of the company from its parent, Novartis, expected later this year.
She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of
the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing
the sustainability of our industry so we can continue to play our vital part in the health of the nation."
Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through
her role on the BGMA board and leadership of a key strategic committee.
British pharmaceutical giant GlaxoSmithKline beat first-quarter sales and earnings forecasts on Wednesday (April 27), helped by demand for its Covid-19 therapy
and shingles vaccine, as the company moves towards the July separation of its consumer health business.
Profit after tax jumped 68 percent to £1.8 billion ($2.3 billion, 2.1 billion euros) compared with the start of 2021.
Sales climbed 32 percent to almost £9.8 billion.
"We have delivered strong first-quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth," chief
executive Emma Walmsley said in the earnings statement.
"Our results reflect further good momentum across speciality medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress."
The shingles vaccine generated £698 million in quarterly sales, beating analyst estimates of 528 million.
Walmsley is seeking to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.
Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what
to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26).
The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA).
NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA
head of advice and support services Jasmine Shah.
Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost
and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient
at the centre of all this and the potential confusion for them."
Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to
take the accountability as far as patient care goes".
She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and
spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and
seeing what is the safest way for them to receive care from both spoke and hub."
The Association of the British Pharmaceutical Industry (ABPI) has issued a challenge to all political parties to outline detailed plans aimed at maximising
the industry's role in driving UK health and economic prosperity.
In 2022, the pharmaceutical sector invested £9 billion in UK research and development, generating £16.4 billion in economic value and sustaining 126,000 high-skilled
jobs nationwide.
Ahead of the 2024 general elections, ABPI's Manifesto for Investment, Health, and Growth outlines a strategic framework to enhance patient care within the NHS.
It includes expanding access to new medicines through clinical trials and bolstering domestic manufacturing capabilities.
It also includes creating additional high-skilled employment opportunities across the UK.
As per the association, the potential impact of these initiatives is substantial.
Instability in the supply chain network is frequently undermining the profit margins in community pharmacies, former Pharmacy Minister and Chair of the Health
and Social Care Committee Steve Brine has said.
Brine emphasised that community pharmacies often lack information about the prices wholesalers charge for essential generic medications. "They lack visibility
into scarcity, and the pricing of these products is often significantly higher compared to other European countries," the former minister remarked during a
parliamentary debate focused on the future of community pharmacies on September 14.
From financial pressures to workforce crisis and pharmacy closures, the debate delved into critical challenges faced by pharmacies, aiming to propose tangible
solutions for a sustainable future in the sector.
Chaired by Sir Mark Hendrik, the debate was initiated by Conservative MP Peter Aldous and featured contributions from a host of participants including Labour MPs
Taiwo Owatemi and George Howarth among others.
The trade bodies and four largest pharmacy chains in England, have jointly written to the Secretary of State for Health, Steve Barclay, warning that the sector
needs urgent investment for sustainability.
The letter from AIMp, CCA, NPA, PSNC, Boots UK, Lloyds Pharmacy, Well, and Phoenix UK, warned that the 30 per cent real terms funding cuts that pharmacies have faced
over the past seven years have left many businesses in a cashflow crisis.
The letter said that the government is facing a choice over the future of the country's 11,000+ community pharmacies, with permanent closures likely and medicines
supply at risk if no urgent action is taken.
"If the funding situation is not addressed, the sector is likely to move rapidly towards many permanent closures of pharmacies."
The organisations say that once these closures start, they will be hard to stop, as the sector is now so fragile other pharmacies would struggle to pick up the slack.
The Pharmaceutical Services Negotiating Committee (PSNC)'s members are seeking immediate rescue packages for the sector to help with energy bills and to ease
capacity constraints.
In a meeting held on 14th and 15th September, the committee members expressed their anger and frustration on the reluctance of NHS England and government to fund
pharmacy sustainably.
The meeting was held to consider practical steps to ease the pressures on the community pharmacy sector, and to oversee the progress of negotiations on the Community
Pharmacy Contractual Framework (CPCF) and other work.
Committee members, as pharmacy contractors, shared their experiences of the current pressures on all contractors, including the inability to deliver some services
and to maintain core service levels; the capacity and workforce crises facing the sector; the critical need for funding support this winter; and the urgent need for
Government to adapt the Price Concessions system to meet the needs of contractors.
"The Price Concessions system is no longer working for contractors in the current volatile medicine supply environment and PSNC is clear this is not acceptable,"
said the committee.
In a stirring address at the recent conference on Pharmacy at the Westminster Health Forum, Director of NHS Services at Community Pharmacy England (CPE),
Alastair Buxton presented a stark assessment of the community pharmacy sector's challenges.
Highlighting years of financial constraints imposed by the NHS and government, Buxton warned of a sector teetering on the edge of survival.
"There have been no years of financial and operational squeezes applied by the NHS and
government to the community pharmacy sector, so as a consequence, there are a lot of pharmacies that are on the on the brink of survival -battling for survival,"
he said.
Buxton underscored the critical and indispensable role of community pharmacies in delivering essential NHS services, from dispensing medications to innovative
initiatives like the Discharge Medicine Service and Contraception Service.